Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Alere Acquires Epocal for USD 166 Million

By Labmedica International staff writers
Posted on 18 Feb 2013
Alere Inc. (Waltham, MA, USA) has acquired Epocal, Inc., (Ottawa, Canada) a provider of technologies that support blood gas and electrolyte testing at the point of care (POC).

In 2009, the two companies entered into an agreement for Alere to acquire all of Epocal’s issued and outstanding equity securities, contingent upon the achievement of gross margin and other financial milestones on or before October 31, 2014. The company did not disclose what those specific milestones were.

By developing new capabilities in near-patient diagnosis, monitoring, and health information solutions, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, infectious disease, toxicology, and diabetes.

Commenting on the acquisition, Alere CEO, Ron Zwanziger, stated, “Through its unique combination of novel diagnostic parameters and wireless-enabled technology, Epocal has set new standards in helping healthcare practitioners in critical settings deliver better patient outcomes, all the while establishing clinical efficiencies. These achievements are core to Alere’s broader mission of empowering individuals and their physicians with data that drive more responsive decision making and improved health outcomes, and we welcome Epocal into the Alere family.”

Related Links:

Alere
Epocal



DRG International
DiagCor Bioscience
77 ELEKTRONIKA
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel

Heart Attack Biomarkers Accurate in Chronic Kidney Disease Patients

Two blood peptide biomarkers that are indicators of heart attack in the general population also provide critical information regarding heart status in chronic kidney disease patients. High-sensitivity troponin T (hsTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) strongly predict heart failure (HF) in the... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.